Matthew Korenberg - 28 Jun 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: President & Chief Operating
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg
Issuer symbol: LGND
Transactions as of: 28 Jun 2024
Transactions value $: $21,247
Form type: 4
Filing time: 02 Jul 2024, 19:45:27 UTC
Previous filing: 15 May 2024
Next filing: 13 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Other	$21.2K	+350	+0.41%	$60.71	86.6K	28 Jun 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).